MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study

Trial Profile

MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Biotin (Primary)
  • Indications Adrenomyeloneuropathy
  • Focus Therapeutic Use
  • Acronyms MD1003-AMN
  • Sponsors MedDay Pharmaceuticals
  • Most Recent Events

    • 06 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2017 This trial has been completed in Spain, according to European Clinical Trials Database record.
    • 26 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top